ClinicalTrials.gg
RecruitingNCT06886815Updated Nov 16, 2026

Popliteal Nerve Block for Acute Achilles Tendon Rupture Repair Surgery

An interventional study of Popliteal Nerve Block and Sham Block in Acute Achilles Tendon Rupture, sponsored by Women's College Hospital. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Women's College Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Achilles tendon rupture is common, yet the value of popliteal nerve block for postoperative pain control during surgical repair remains uncertain. Despite widespread use, evidence supporting its analgesic effectiveness is limited, and both popliteal nerve block and Achilles tendon repair carry risks of nerve injury. This randomized, placebo-controlled trial will evaluate whether adding a popliteal nerve block to standard systemic analgesia improves postoperative pain and reduces opioid use in patients undergoing acute Achilles tendon rupture repair. Secondary outcomes will examine the incidence and impact of nerve complications on recovery, including return to physical activity and functional performance.

Read the detailed description

This will be a prospective, double-blinded, randomized controlled superiority trial conducted at Women's College Hospital (WCH). The study aims to enroll 80 patients (40 per group) undergoing ambulatory surgical repair of acute Achilles tendon ruptures.

02

Conditions studied

  • Acute Achilles Tendon Rupture

Keywords

  • Popliteal Nerve Block
  • Lower Extremity Regional Anesthesia
  • Achilles Tendon
03

In context

Lead sponsor

Women's College Hospital is the lead sponsor of 87 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 65
  • : I - III
  • \< 35 kg/m2
  • Undergoing acute Achilles tendon rupture repair surgery as a day surgery procedure

Exclusion criteria

Exclusion Criteria:

  • Pre-existing neurological deficits or peripheral neuropathy in the distribution of the tibial or common peroneal nerves
  • Local infection
  • to regional anesthesia (e.g., bleeding diathesis, coagulopathy)
  • History of use of over 30 mg oxycodone or equivalent per day
  • Contraindication to any component of a standard multi-modal analgesia
  • Allergy to local anesthetics
  • History of significant psychiatric conditions that may affect patient assessment
  • Pregnancy
  • Inability to provide
  • Patient refusal of popliteal nerve blockade
  • Prior Achilles tendon surgeries on the operative leg
  • Unable to speak or read English
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Popliteal nerve (PN) block group

    30 mL of 0.5% ropivacaine with 2.5 µg/ml of epinephrine

    Procedure: Popliteal Nerve Block

  • Sham comparator
    Placebo Nerve Block

    1 mL of saline

    Procedure: Sham Block

Interventions

  • ProcedurePopliteal Nerve Block

    Under ultrasound guidance, a 22G, 80-mm echogenic needle (SonoTAP II, Pajunk Medical Systems, USA) will be inserted using an in-plane lateral-to-medial approach. 30 mL of 0.5% ropivacaine with 2.5 µg/ml of epinephrine will be deposited between tibial and common peroneal nerves within the paraneural sheath. Adequate spread of local anesthetics will be confirmed by visualization of paraneural spread.

    Also known as: Popliteal Sciatic Nerve Block

  • ProcedureSham Block

    Patients in the Control group will receive sham blocks using a 25G needle to inject 1 mL of saline subcutaneously in the same location (popliteus of the surgical knee). Sterilization and ultrasound scanning will match actual PN block. Such a non-invasive placebo allows maintaining patient blinding, while reducing the risks associated with high-volume placebo nerve block injections. The ultrasound screen will be blinded from the patient's vision for all patients in the trial to prevent unblinding by patients with knowledge of the technique.

06

What researchers measure

Primary outcomes

  1. Cumulative Opioid Consumption

    Total opioid dose administered to each patient, converted to oral morphine equivalents.

    Time frame: The first 24 hours after surgery

Secondary outcomes

  1. Area Under the Curve for Postoperative Pain

    Area under the curve calculated from discrete Numeric Rating Scale evaluations of postoperative pain (0 - 10), where 0 corresponds to no pain, and 10 corresponds to the worst pain imaginable. Pain will be measured on this scale at 0, 6, 12, 18, and 24 hours after surgery.

    Time frame: The first 24 hours after surgery

  2. Quality of Recovery

    Quality of recovery evaluated using the QoR-15 scale (0 - 150), where 0 represents extremely poor recovery and 150 represents excellent recovery.

    Time frame: At baseline, 6, 24, 48 hours, 7 days and 1-year post-surgery

  3. Postoperative Pain Score

    Measured using the Numeric Rating (NRS) Scale (0 - 10) where 0 corresponds to no pain, and 10 corresponds to the worst pain imaginable.

    Time frame: At baseline, 0, 6, 12, 18, 24, 36, 48 hours, 7 days and 1-year post-surgery.

  4. Intraoperative Opioid Consumption

    Measurement of opioids administered during surgery, converted into oral morphine equivalents.

    Time frame: The first 24 hours after surgery

  5. Time to Analgesic Request

    Length of time until the patient's first request for analgesics following surgery.

    Time frame: The first 24 hours after surgery

  6. Time to Discharge

    The length of time each patient stays in Phase I (Postanesthesia Care Unit) and Phase II (Surgical Day Care) after surgery.

    Time frame: The first 24 hours after surgery

  7. Adverse Events Attributable to Popliteal Block

    The incidence of adverse events possibly attributable to popliteal nerve block, including peripheral nerve injury, hematoma, and infection.

    Time frame: At 0, 6, 12, 18, 24, 36, 48 hours, 7 days and 1-year post-surgery

  8. Adverse Events Attributable to Opioids

    The incidence of opioid-related side effects, including sedation, pruritis, nausea/vomiting, and respiratory depression.

    Time frame: Evaluated at 24 and 48 hours after surgery.

  9. Pain, fatigue, and physical function

    Measured using the Achilles tendon Total Rupture Score (ATRS)

    Time frame: Prior to surgery and 1-year post-surgery

  10. Neuropathic pain

    Measured using the English version of the Douleur Neuropathique 4 (DN4) Questionnaire

    Time frame: At 1 week and 1-year post-surgery

07

Study locations

1 of 1 sites recruiting
  • Women's College Hospital
    Toronto, Ontario M5S 1B2, Canada
    Recruiting
    • Didem Bozak · Contactdidem.bozak@wchospital.ca · 416-323-6008
    • Richard Brull, MD,FRCPC · Principal investigator
    • Connor TA Brenna, MD · Sub investigator
    • Seung C Kim, MD,FFPMRCA · Sub investigator
    • Faraj W Abdallah, MD,FRCPC · Sub investigator
    • Sam Park, MD,MASc · Sub investigator
08

References and documents

Publications

  • Brenna CTA, Khan S, Abdallah FW, Brull R. Achilles Hero or Heel? A Systematic Review of Popliteal Nerve Block for Achilles Repair. Foot & Ankle Surgery: Techniques, Reports & Cases. 2025:100474.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Mar 20, 2025
StartActual
Mar 17, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Mar 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06886815
Lead sponsor
Women's College Hospital
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
Mar 17, 2026
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Didem Bozak
Contact
didem.bozak@wchospital.ca
416-323-6008
Richard Brull, MD, FRCPC
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion